Minocycline add-on to risperidone for treatment of negative symptoms in patients with stable schizophrenia: randomized double-blind placebo-controlled study.
Abstract
The objective of this study was to assess the efficacy and tolerability of minocycline add-on to risperidone in treatment of negative symptoms of patients with chronic schizophrenia. In a randomized double-blind placebo-controlled study, 40 patients with chronic schizophrenia who were stabilized on risperidone for a minimum duration of eight weeks were recruited. The patients were randomly assigned to minocycline (titrated up to 200 mg/day) or placebo in addition to risperidone (maximum dose of 6 mg/day) for eight weeks. Positive and Negative Syndrome Scale (PANSS), Hamilton Depression Rating Scale, and Extrapyramidal Syndrome Rating Scale were used. Thirty-eight patients completed the study. Significant time × treatment interaction for negative [F(2.254,85.638)=59.046, P<0.001] general psychopathology [F(1.703,64.700)=6.819, P=0.001], and positive subscales [F(1.655,62.878)=5.193, P=0.012] as well as total PANSS scores [F(1.677,63.720)=28.420, P<0.001] were observed. The strongest predictors for change in negative symptoms were the treatment group (β=-0.94, t=-10.59, P<0.001) followed by the change in PANSS positive subscale (β=-0.185, t=-2.075, P=0.045). Side effect profiles of the two treatment regimens were not significantly different. Minocycline seems to be an efficacious and tolerable short-term add-on to risperidone for treatment of negative and general psychopathology symptoms of schizophrenia.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Clinical trials using minocycline alone or as an adjunct to risperidone in patients with schizophrenia have demonstrated overall improvement in negative symptoms and executive functioning.
“Various clinical trials have been conducted using minocycline alone or as an adjunct to risperidone in patients with schizophrenia and have demonstrated overall improvement in negative symptoms and executive functioning (Miyaoka et al., 2008; Levkovitz et al., 2010; Khodaie-Ardakani et al., 2014).”
From The Perineuronal ‘Safety’ Net? Perineuronal Net Abnormalities in Neurological Disorders (2018) · cites this paper as Khodaie-Ardakani et al., 2014
Cites
Hamilton, M. (1960) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.23.1.56 · Cited by 32,817 · see citing works
The Positive and Negative Syndrome Scale (PANSS) for schizophrenia.
Kay, S. R., Fiszbein, A., & Opler, L. A. (1987) · Schizophrenia Bulletin · doi:10.1093/schbul/13.2.261 · Cited by 21,378 · see citing works
Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis
Leucht, S., Corves, C., Arbter, D., Engel, R. R., Li, C., & Davis, J. M. (2009) · The Lancet · doi:10.1016/s0140-6736(08)61764-x · Cited by 1,930 · see citing works
The NIMH-MATRICS Consensus Statement on Negative Symptoms
Kirkpatrick, B., Fenton, W. S., Carpenter, W. T., & Marder, S. R. (2006) · Schizophrenia Bulletin · doi:10.1093/schbul/sbj053 · Cited by 1,311 · see citing works
Yrjänheikki, J., Kauppinen, T. M., Keinänen, R., Goldsteins, G., Chan, P. H., & Koıstınaho, J. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.23.13496 · Cited by 1,040 · see citing works
Du, Y., Ma, Z., Lin, S., Dodel, R. C., Gao, F., Bales, K. R., Triarhou, L. C., Chernet, E., Perry, K. W., Nelson, D. L. G., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.251341998 · Cited by 789 · see citing works
A novel mechanism of action of tetracyclines: Effects on nitric oxide synthases
Amin, A. R., Attur, M. G., Thakker, G. D., Patel, P. D., Vyas, P., Patel, R. N., Patel, I. R., & Abramson, S. B. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.24.14014 · Cited by 474 · see citing works
Persistent Negative Symptoms in Schizophrenia: An Overview
Buchanan, R. W. (2006) · Schizophrenia Bulletin · doi:10.1093/schbul/sbl057 · Cited by 443 · see citing works
Manual for the Extrapyramidal Symptom Rating Scale (ESRS)
Chouinard, G., & Margolese, H. C. (2005) · Schizophrenia Research · doi:10.1016/j.schres.2005.02.013 · Cited by 418 · see citing works
Wang, X., Zhu, S., Drozda, M., Zhang, W., Stavrovskaya, I. G., Cattaneo, E. F., Ferrante, R. J., Kristal, B. S., & Friedlander, R. M. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1832501100 · Cited by 407 · see citing works
Kantrowitz, J. T., & Javitt, D. C. (2010) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2010.04.006 · Cited by 397 · see citing works
Levkovitz, Y., Mendlovich, S., Riwkes, S., Braw, Y., Levkovitch-Verbin, H., Gal, G., Fennig, S., Treves, I., & Kron, S. (2010) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.08m04666yel · Cited by 387 · see citing works
Tsai, G. E., Lane, H., Yang, P., Chong, M., & LANGE, N. D. (2004) · Biological Psychiatry · doi:10.1016/j.biopsych.2003.09.012 · Cited by 343 · see citing works
Akhondzadeh, S., Tabatabaee, M., AMINI, H., Ahmadi-Abhari, S.-A., ABBASI, S., & BEHNAM, B. (2007) · Schizophrenia Research · doi:10.1016/j.schres.2006.11.016 · Cited by 290 · see citing works
Self-citationChaudhry, I. B., Hallak, J. E. C., Husain, N., Minhas, F., Stirling, J., Richardson, P., Dursun, S. M., Dunn, G., & Deakin, J. F. W. (2012) · Journal of Psychopharmacology · doi:10.1177/0269881112444941 · Cited by 281 · see citing works
Minocycline Up-regulates Bcl-2 and Protects against Cell Death in Mitochondria
Wang, J., Wei, Q., Wang, C., Hill, W., Hess, D. C., & Dong, Z. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m313629200 · Cited by 242 · see citing works
Pharmacokinetic studies on minocycline in man
Macdonald, H., Kelly, R. G., Allen, E. S., Noble, J. F., & Kanegis, L. A. (1973) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt1973145852 · Cited by 222 · see citing works
Pharmacological treatment of primary negative symptoms in schizophrenia: A systematic review
Murphy, B., Chung, Y., Park, T.-W., & McGorry, P. D. (2006) · Schizophrenia Research · doi:10.1016/j.schres.2006.07.002 · Cited by 217 · see citing works
Glutamatergic drugs for schizophrenia: a systematic review and meta-analysis
Tuominen, H. J., Tiihonen, J., & Wahlbeck, K. (2004) · Schizophrenia Research · doi:10.1016/j.schres.2004.05.005 · Cited by 209 · see citing works
Additive neuroprotective effects of minocycline with creatine in a mouse model of ALS
Zhang, W., Narayanan, M. V., & Friedlander, R. M. (2003) · Annals of Neurology · doi:10.1002/ana.10476 · Cited by 185 · see citing works
Minocycline as Adjunctive Therapy for Schizophrenia: An Open-Label Study
Miyaoka, T., Yasukawa, R., Yasuda, H., Hayashida, M., Inagaki, T., & Horiguchi, J. (2008) · Clinical Neuropharmacology · doi:10.1097/wnf.0b013e3181593d45 · Cited by 146 · see citing works
Pi, R., Li, W., Lee, N. T. K., Chan, H. H. N., Pu, Y., Chan, L. N., Sucher, N. J., Chang, D. C., Li, M., & Han, Y. (2004) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2004.02796.x · Cited by 145 · see citing works
Zhang, L., Shirayama, Y., Iyo, M., & Hashimoto, K. (2007) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301313 · Cited by 105 · see citing works
Fujita, Y., Ishima, T., Kunitachi, S., Hagiwara, H., Zhang, L., Iyo, M., & Hashimoto, K. (2007) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2007.08.031 · Cited by 99 · see citing works
Chaves, C., de Marque, C. R., Trzesniak, C. M. F., de Sousa, J. P. M., Zuardi, A. W., Crippa, J. A. S., Dursun, S. M., & Hallak, J. E. C. (2009) · Brazilian Journal of Medical and Biological Research · doi:10.1590/s0100-879x2009001100002 · Cited by 64 · see citing works
Rezaei, F., Mohammad-karimi, M., Seddighi, S., Modabbernia, A., Ashrafi, M., Salehi, B., Hammidi, S., Motasami, H., Hajiaghaee, R., Tabrizi, M. H., et al. (2013) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31828b50a7 · Cited by 56 · see citing works
Self-citationFarokhnia, M., Sabzabadi, M., Pourmahmoud, H., Khodaie-Ardakani, M.-R., Hosseini, S.-M.-R., Yekehtaz, H., Tabrizi, M. H., Rezaei, F., Salehi, B., & Akhondzadeh, S. (2013) · Psychopharmacology · doi:10.1007/s00213-013-3261-z · Cited by 47 · see citing works
Self-citationAkhondzadeh, S., Ghayyoumi, R., Rezaei, F., Salehi, B., Modabbernia, A., Maroufi, A., Esfandiari, G.-R., Naderi, M., Ghebleh, F., Tabrizi, M. H., et al. (2010) · Psychopharmacology · doi:10.1007/s00213-010-2044-z · Cited by 45 · see citing works
Self-citationPossible anti-catatonic effects of minocycline in patients with schizophrenia
Ahuja, N., & Carroll, B. T. (2007) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2007.01.018 · Cited by 41 · see citing works
Maintained improvement with minocycline of a patient with advanced Huntington's disease
Denovan‐Wright, E. M., Devarajan, S., Dursun, S. M., & Robertson, H. A. (2002) · Journal of Psychopharmacology · doi:10.1177/026988110201600417 · Cited by 29 · see citing works
A placebo-controlled study of the modafinil added to risperidone in chronic schizophrenia
Arbabi, M., Bagheri, M., Rezaei, F., Ahmadi-Abhari, S.-A., Tabrizi, M. H., Khalighi‐Sigaroodi, F., & Akhondzadeh, S. (2011) · Psychopharmacology · doi:10.1007/s00213-011-2513-z · Cited by 28 · see citing works
Self-citationGhaleiha, A., Noorbala, A. A., Farnaghi, F., Hajiazim, M., & Akhondzadeh, S. (2010) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e3181fa8720 · Cited by 27 · see citing works
Self-citationMinocycline slows progress of Huntington's disease in mice
Berger, A. (2000) · BMJ · doi:10.1136/bmj.321.7253.70 · Cited by 22 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Gut instincts: microbiota as a key regulator of brain development, ageing and neurodegeneration
Dinan, T. G., & Cryan, J. F. (2017) · The Journal of Physiology · doi:10.1113/jp273106 · Cited by 813 · see citing works
Millan, M. J., Fone, K. C. F., Steckler, T., & Horan, W. P. (2014) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2014.03.008 · Cited by 354 · see citing works
Cross talk: the microbiota and neurodevelopmental disorders
Kelly, J. R., Minuto, C., Cryan, J. F., Clarke, G., & Dinan, T. G. (2017) · Frontiers in Neuroscience · doi:10.3389/fnins.2017.00490 · Cited by 271 · see citing works
The impact of gut microbiota on brain and behaviour
Dinan, T. G., & Cryan, J. F. (2015) · Current Opinion in Clinical Nutrition & Metabolic Care · doi:10.1097/mco.0000000000000221 · Cited by 267 · see citing works
Microbes, immunity, and behavior: psychoneuroimmunology meets the microbiome
Dinan, T. G., & Cryan, J. F. (2017) · Neuropsychopharmacology · doi:10.1038/npp.2016.103 · Cited by 246 · see citing works
Çakici, N., van Beveren, N. J. M., Judge-Hundal, G., Koola, M. M., & Sommer, I. E. (2019) · Psychological Medicine · doi:10.1017/s0033291719001995 · Cited by 215 · see citing works
The Perineuronal ‘Safety’ Net? Perineuronal Net Abnormalities in Neurological Disorders
Wen, T. H., Binder, D. K., Ethell, I. M., & Razak, K. A. (2018) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2018.00270 · Cited by 170 · see citing works
Treating Negative Symptoms in Schizophrenia: an Update
Remington, G. J., Foussias, G., Fervaha, G., Agid, O., Takeuchi, H., Lee, J., & Hahn, M. (2016) · Current Treatment Options in Psychiatry · doi:10.1007/s40501-016-0075-8 · Cited by 167 · see citing works
Glutamatergic dysfunction in Schizophrenia
Kruse, A. O., & Bustillo, J. (2022) · Translational Psychiatry · doi:10.1038/s41398-022-02253-w · Cited by 154 · see citing works
Jeppesen, R., Christensen, R. H. B., Pedersen, E. M. J., Nordentoft, M., Hjorthøj, C., Köhler-Forsberg, O., & Benros, M. E. (2020) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2020.08.028 · Cited by 132 · see citing works
Schizophrenia and the gut–brain axis
Nemani, K., Hosseini Ghomi, R., McCormick, B., & Fan, X. (2015) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2014.08.018 · Cited by 151 · see citing works
Giovanoli, S., Engler, H., Engler, A., Richetto, J., Feldon, J., Riva, M. A., Schedlowski, M., & Meyer, U. (2016) · Translational Psychiatry · doi:10.1038/tp.2016.38 · Cited by 125 · see citing works
Cho, M., Lee, T. Y., Kwak, Y. B., Yoon, Y. B., Kim, M., & Kwon, J. S. (2019) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867419835028 · Cited by 128 · see citing works
Cattane, N., Richetto, J., & Cattaneo, A. (2018) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2018.07.001 · Cited by 118 · see citing works
The role of the gut microbiome in the development of schizophrenia
Kelly, J. R., Minuto, C., Cryan, J. F., Clarke, G. A., & Dinan, T. G. (2020) · Schizophrenia Research · doi:10.1016/j.schres.2020.02.010 · Cited by 119 · see citing works
Tewari, B. P., Chaunsali, L., Prim, C. E., & Sontheimer, H. W. (2022) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2022.1022754 · Cited by 107 · see citing works
Adjunctive Minocycline in Clozapine-Treated Schizophrenia Patients With Persistent Symptoms
Kelly, D. L., Sullivan, K. M., McEvoy, J. P., McMahon, R. P., Wehring, H. J., Gold, J. M., Liu, F., Warfel, D. T., Vyas, G. R., Richardson, C. M., et al. (2015) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000345 · Cited by 102 · see citing works
Arabzadeh, S., Ameli, N., Zeinoddini, A., Rezaei, F., Farokhnia, M., Mohammadinejad, P., Ghaleiha, A., & Akhondzadeh, S. (2015) · Bipolar Disorders · doi:10.1111/bdi.12324 · Cited by 100 · see citing works
Self-citationSepehrmanesh, Z., Heidary, M., Akasheh, N., Akbari, H., & Heidary, M. (2017) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2017.11.001 · Cited by 97 · see citing works
Nasyrova, R. F., Ivashchenko, D. V., Ivanov, M. V., & Незнанов, Н. Г. (2015) · Frontiers in Physiology · doi:10.3389/fphys.2015.00139 · Cited by 98 · see citing works
Minocycline in neurodegenerative and psychiatric diseases: An update
Romero‐Miguel, D., Lamanna‐Rama, N., Casquero‐Veiga, M., Gómez‐Rangel, V., Desco, M., & Soto‐Montenegro, M. L. (2020) · European Journal of Neurology · doi:10.1111/ene.14642 · Cited by 95 · see citing works
Adjunctive minocycline for schizophrenia: A meta-analysis of randomized controlled trials
Xiang, Y.-Q., Zheng, W., Wang, S.-B., Yang, X.-H., Cai, D.-B., Ng, C. H., Ungvari, G. S., Kelly, D. L., Xu, W.-Y., & Xiang, Y.-T. (2016) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2016.11.012 · Cited by 83 · see citing works
Systematic review and meta-analysis of the efficacy and safety of minocycline in schizophrenia
Solmi, M., Veronese, N., Thapa, N., Facchini, S., Stubbs, B., Fornaro, M., Carvalho, A. F., & Correll, C. U. (2017) · CNS Spectrums · doi:10.1017/s1092852916000638 · Cited by 78 · see citing works
Modulating Neuroinflammation to Treat Neuropsychiatric Disorders
Radtke, F., Chapman, G., Hall, J., & Syed, Y. A. (2017) · BioMed Research International · doi:10.1155/2017/5071786 · Cited by 76 · see citing works
Therapeutic effects of minocycline on mild-to-moderate depression in HIV patients
Emadi-Kouchak, H., Mohammadinejad, P., Asadollahi‐Amin, A., Rasoulinejad, M., Zeinoddini, A., Yalda, A., & Akhondzadeh, S. (2015) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000098 · Cited by 76 · see citing works
Self-citationGirgis, R. R., Zoghbi, A. W., Javitt, D. C., & Lieberman, J. A. (2018) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2018.07.006 · Cited by 73 · see citing works
Clinical management of negative symptoms of schizophrenia: An update
Tsapakis, E.-M., Dimopoulou, T., & Tarazi, F. I. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2015.06.008 · Cited by 72 · see citing works
Oya, K., Kishi, T., & Iwata, N. (2014) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.2426 · Cited by 69 · see citing works
Panizzutti, B., Skvarc, D., Lin, S. C., Croce, S., Meehan, A., Bortolasci, C. C., Marx, W., Walker, A. J., Hasebe, K., Kavanagh, B. E., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24065250 · Cited by 70 · see citing works
Esalatmanesh, S., Abrishami, Z., Zeinoddini, A., Rahiminejad, F., Sadeghi, M., Najarzadegan, M., Shalbafan, M., & Akhondzadeh, S. (2016) · Psychiatry and Clinical Neurosciences · doi:10.1111/pcn.12430 · Cited by 65 · see citing works
Self-citationThe microbiome and disorders of the central nervous system
Felice, V. D., & O'Mahony, S. M. (2017) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2017.06.016 · Cited by 60 · see citing works
Zhang, L., Zheng, H., Wu, R., Zhu, F., Kosten, T. R., Zhang, X., & Zhao, J. (2018) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2018.04.004 · Cited by 59 · see citing works
Wu, Q., Wang, X., Wang, Y., Long, Y., Zhao, J., & Wu, R. (2021) · Neuroscience Bulletin · doi:10.1007/s12264-021-00740-6 · Cited by 56 · see citing works
Iranpour, N., Zandifar, A., Farokhnia, M., Goguol, A., Yekehtaz, H., Ardakani, M. R. K., Salehi, B., Esalatmanesh, S., Zeionoddini, A., Mohammadinejad, P., et al. (2016) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.2517 · Cited by 56 · see citing works
Self-citationGhaleiha, A., Alikhani, R., Kazemi, M.-R., Mohammadi, M.-R., Mohammadinejad, P., Zeinoddini, A., Hamedi, M., Shahriari, M., Keshavarzi, Z., & Akhondzadeh, S. (2016) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2015.0175 · Cited by 56 · see citing works
Self-citationAnti-inflammatory medications for the treatment of mental disorders: A scoping review
Fitton, R., Sweetman, J., Heseltine-Carp, W., & van der Feltz-Cornelis, C. (2022) · Brain, Behavior, & Immunity - Health · doi:10.1016/j.bbih.2022.100518 · Cited by 53 · see citing works
Murrough, J. W., Huryk, K. M., Mao, X., Iacoviello, B. M., Collins, K. A., Nierenberg, A. A., Kang, G., Shungu, D. C., & Iosifescu, D. V. (2018) · Journal of Affective Disorders · doi:10.1016/j.jad.2017.12.067 · Cited by 54 · see citing works
Minichino, A., Brondino, N., Solmi, M., Del Giovane, C., Fusar-Poli, P., Burnet, P., Cipriani, A., & Lennox, B. R. (2021) · Schizophrenia Research · doi:10.1016/j.schres.2020.02.012 · Cited by 50 · see citing works
Kianimehr, G., Fatehi, F., Hashempoor, S., Ardakani, M. R. K., Rezaei, F., Nazari, A., Kashani, L., & Akhondzadeh, S. (2014) · DARU Journal of Pharmaceutical Sciences · doi:10.1186/2008-2231-22-55 · Cited by 50 · see citing works
Self-citationSoczynska, J. K., Kennedy, S. H., Alsuwaidan, M. T., Mansur, R. B., Li, M., McAndrews, M. P., Brietzke, E. M., Woldeyohannes, H. O., Taylor, V. H., & McIntyre, R. S. (2017) · Bipolar Disorders · doi:10.1111/bdi.12496 · Cited by 49 · see citing works
The effect of minocycline on symptoms in schizophrenia: Results from a randomized controlled trial
Weiser, M., Levi, L. W., Burshtein, S., Chiriță, R., Cirjaliu, D., Gonen, I., Yolken, R. H., Davidson, M., Zamora, D., & Davis, J. M. (2018) · Schizophrenia Research · doi:10.1016/j.schres.2018.10.023 · Cited by 48 · see citing works
The role of the gut microbiota in schizophrenia: Current and future perspectives
Rodrígues-Amorím, D., Baltanás, T. R., Regueiro, B. J., Spuch, C., Heras, M. E. D. L., Méndez, R. V.-N., Nieto-Araujo, M., Barreiro-Villar, C., Olivares, J. M., & Agís‐Balboa, R. C. (2018) · The World Journal of Biological Psychiatry · doi:10.1080/15622975.2018.1433878 · Cited by 47 · see citing works
Volk, D. W. (2016) · Neurobiology of Disease · doi:10.1016/j.nbd.2016.12.019 · Cited by 47 · see citing works
Memantine in neurological disorders – schizophrenia and depression
Czarnecka, K., Chuchmacz, J., Wójtowicz, P., & Szymański, P. (2021) · Journal of Molecular Medicine · doi:10.1007/s00109-020-01982-z · Cited by 46 · see citing works
Efficacy of Memantine in Schizophrenic Patients: A Systematic Review
Iorio, G. D., Baroni, G., Lorusso, M., Montemitro, C., Spano, M. C., & Giannantonio, M. D. (2017) · Journal of Amino Acids · doi:10.1155/2017/7021071 · Cited by 41 · see citing works
Amidfar, M., Khiabany, M., Kohi, A., Salardini, E., Arbabi, M., Azizi, M. R., Zarrindast, M., Mohammadinejad, P., Zeinoddini, A., & Akhondzadeh, S. (2016) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.12469 · Cited by 40 · see citing works
Self-citationEffects of Antipsychotic Drugs: Cross Talk Between the Nervous and Innate Immune System
Dinesh, A. A., Islam, J., Khan, J., Turkheimer, F., & Vernon, A. C. (2020) · CNS Drugs · doi:10.1007/s40263-020-00765-x · Cited by 39 · see citing works
Hadi, F., Kashefinejad, S., Kamalzadeh, L., Hoobehfekr, S., & Shalbafan, M. (2021) · BMC Pharmacology and Toxicology · doi:10.1186/s40360-021-00534-6 · Cited by 36 · see citing works
Adjunctive minocycline for major mental disorders: A systematic review
Zheng, W., Zhu, X., Zhang, Q., Cheng, G., Cai, D.-B., He, J., Ng, C. H., Ungvari, G. S., Peng, X.-J., Ning, Y., et al. (2019) · Journal of Psychopharmacology · doi:10.1177/0269881119858286 · Cited by 37 · see citing works
Simvastatin adjunct therapy for negative symptoms of schizophrenia
Tajik-Esmaeeli, S., Zadeh, E. M., Abbasi, N., Shariat, S. V., Rezaei, F., Salehi, B., & Akhondzadeh, S. (2016) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000159 · Cited by 36 · see citing works
Self-citationAn emerging role of cGMP in the treatment of schizophrenia: A review
Shim, S. S., Shuman, M. D., & Duncan, E. (2015) · Schizophrenia Research · doi:10.1016/j.schres.2015.11.015 · Cited by 35 · see citing works
Neuroinflammation and oxidative stress in schizophrenia: are these opportunities for repurposing?
Ansari, Z., Pawar, S. R., & Seetharaman, R. (2021) · Postgraduate Medicine · doi:10.1080/00325481.2021.2006514 · Cited by 35 · see citing works
Drug repurposing and emerging adjunctive treatments for schizophrenia
Bumb, J. M., Enning, F., & Leweke, F. M. (2015) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2015.1032248 · Cited by 34 · see citing works
Pérez‐Gómez, A., Carretero, M., Weber, N., Peterka, V., To, A., Titova, V., Solis, G. M., Osborn, O., & Petrascheck, M. (2018) · Nature Communications · doi:10.1038/s41467-018-07684-y · Cited by 33 · see citing works
Anti-inflammatory effects of minocycline are mediated by retinoid signaling
Clemens, V., Regen, F., Bret, N. L., Heuser, I., & Hellmann‐Regen, J. (2018) · BMC Neuroscience · doi:10.1186/s12868-018-0460-x · Cited by 32 · see citing works
Ardakani, M. R. K., Seddighi, S., Modabbernia, A., Rezaei, F., Salehi, B., Ashrafi, M., Shams‐Alizadeh, N., Mohammad-karimi, M., Esfandiari, G.-R., Hajiaghaee, R., et al. (2013) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2013.01.011 · Cited by 29 · see citing works
Self-citationZeinoddini, A., Ahadi, M., Farokhnia, M., Rezaei, F., Tabrizi, M. H., & Akhondzadeh, S. (2014) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2014.08.016 · Cited by 27 · see citing works
Self-citationJafari, S., Ashrafizadeh, S.-G., Zeinoddini, A., Rasoulinejad, M., Entezari, P., Seddighi, S., & Akhondzadeh, S. (2015) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.12287 · Cited by 27 · see citing works
Self-citationMazinani, R., Nejati, S., & Khodaei, M. (2016) · Psychiatry Research · doi:10.1016/j.psychres.2016.09.028 · Cited by 26 · see citing works
Naderi, S., Faghih, H., Aqamolaei, A., Mortazavi, S. H., Mortezaei, A., Sahebolzamani, E., Rezaei, F., & Akhondzadeh, S. (2018) · Psychiatry and Clinical Neurosciences · doi:10.1111/pcn.12803 · Cited by 25 · see citing works
Self-citationHosseini, S. M. R., Farokhnia, M., Rezaei, F., Gougol, A., Yekehtaz, H., Iranpour, N., Salehi, B., Tabrizi, M. H., Tajdini, M., Ghaleiha, A., et al. (2014) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2014.02.001 · Cited by 23 · see citing works
Self-citationThe Microbiota/Microbiome and the Gut–Brain Axis: How Much Do They Matter in Psychiatry?
Marazziti, D., Buccianelli, B., Palermo, S., Parra, E., Arone, A., Beatino, M. F., Massa, L., Carpita, B., Barberi, F. M., Mucci, F., et al. (2021) · Life · doi:10.3390/life11080760 · Cited by 22 · see citing works
Romero‐Miguel, D., Casquero‐Veiga, M., MacDowell, K. S., Torres-Sánchez, S., Garcia-Partida, J. A., Lamanna‐Rama, N., Romero‐Miranda, A., Berrocoso, E., Leza, J. C., Desco, M., et al. (2021) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyab036 · Cited by 21 · see citing works
Buonaguro, E. F., Tomasetti, C., Chiodini, P., Marmo, F., Latte, G., Rossi, R., Avvisati, L., Iasevoli, F., & de Bartolomeis, A. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116658987 · Cited by 21 · see citing works
Shakiba, M., Zadeh, E. M., Noorbala, A. A., Jafarinia, M., Divsalar, P., Kashani, L., Shahmansouri, N., Tafakhori, A., Bayat, H., & Akhondzadeh, S. (2018) · Europe PMC (PubMed Central) · doi:10.22038/ajp.2018.28835.2020 · Cited by 21 · see citing works
Self-citationLiu, F., Zhang, B., Xie, L., Ruan, Y., Xu, X., Zeng, Y., Messina, L. M., Zhao, J., & Fan, X. (2018) · Schizophrenia Research · doi:10.1016/j.schres.2018.03.003 · Cited by 20 · see citing works
Minocycline as a prospective therapeutic agent for cancer and non-cancer diseases: a scoping review
Rezaei, A., Moqadami, A., & Khalaj‐Kondori, M. (2023) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-023-02839-1 · Cited by 18 · see citing works
Is there a role of gut microbiota in mental health?
Lange, K. W., Lange, K. M., Nakamura, Y. K., & Kanaya, S. (2020) · Journal of Food Bioactives · doi:10.31665/jfb.2020.9213 · Cited by 16 · see citing works
Pharmacological Treatments of Negative Symptoms in Schizophrenia—An Update
Tsapakis, E.-M., Treiber, M., Mitkani, C. A., Drakaki, Z., Cholevas, A., Spanaki, C., & Fountoulakis, K. Ν. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13185637 · Cited by 15 · see citing works
Investigation of TSPO Variants in Schizophrenia and Antipsychotic Treatment Outcomes
Pouget, J. G., Gonçalves, V. F., Nurmi, E. L., Laughlin, C., Mallya, K. S., McCracken, J. T., Aman, M. G., McDougle, C. J., Scahill, L. D., Misener, V. L., et al. (2015) · Pharmacogenomics · doi:10.2217/pgs.14.158 · Cited by 15 · see citing works
Adraoui, F. W., Douw, L., Martens, G. J. M., & Maas, D. A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24097680 · Cited by 14 · see citing works
Comprehensive evaluation of 45 augmentation drugs for schizophrenia: a network meta-analysis
Etchecopar‐Etchart, D., Yon, D. K., Wojciechowski, P., Aballéa, S., Toumi, M., Boyer, L., & Fond, G. B. (2024) · EClinicalMedicine · doi:10.1016/j.eclinm.2024.102473 · Cited by 12 · see citing works
Ameringen, M. V., Fineberg, N. A., Ravindran, A. V., Arnold, P. D., Beaulieu, S., Brakoulias, V., Brietzke, E. M., Dowlati, Y., Drummond, L. M., Ferretti, C. J., et al. (2026) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2025.12.039 · Cited by 10 · see citing works
An Integrated Multi-Omics Approach for AMR Phenotype Prediction of Gut Microbiota
Gao, P., Chen, Z., Wang, D., Huang, M., Ono, N., Altaf‐Ul‐Amin, M., & Kanaya, S. (2021) · IEEE International Conference on Bioinformatics and Biomedicine (BIBM) · doi:10.1109/bibm52615.2021.9669397 · Cited by 9 · see citing works
Minocycline as adjunct therapy for a male patient with deficit schizophrenia
Chen, X., Xiong, Z., Li, Z., Yang, Y., Zheng, Z., Li, Y., Xie, Y., & Li, Z. (2018) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s179658 · Cited by 9 · see citing works
Minocycline for negative symptoms of schizophrenia and possible mechanistic actions: the BeneMin RCT
Deakin, J. F. W., John Suckling, A., Dazzan, P., Joyce, E. M., Lawrie, S. M., Upthegrove, R., Husain, N., Chaudhry, I. B., Dunn, G., Jones, P. B., et al. (2019) · Efficacy and Mechanism Evaluation · doi:10.3310/eme06070 · Cited by 8 · see citing works
Moccia, L., Bardi, F., Anesini, M. B., Barbonetti, S., Kotzalidis, G. D., Rossi, S., Caso, R., Grisoni, F., Mandracchia, G., Margoni, S., et al. (2025) · Biomedicines · doi:10.3390/biomedicines13030540 · Cited by 6 · see citing works
Herrero-Zazo, M., Brauer, R., Gaughran, F., Howard, L. M., Taylor, D. M., & Barlow, D. J. (2017) · Journal of Psychopharmacology · doi:10.1177/0269881117743483 · Cited by 6 · see citing works
Lessons From Clinical Trials of Immunomodulatory Drugs in Psychiatric Disorders
Pak, T. K., Haque, N., & Jha, M. K. (2025) · Biological Psychiatry · doi:10.1016/j.biopsych.2025.11.009 · Cited by 5 · see citing works
Redox and Microglia in the Pathophysiology of Schizophrenia
Kato, T. A., Hyodo, F., Yamato, M., Utsumi, H., & Kanba, S. (2015) · YAKUGAKU ZASSHI · doi:10.1248/yakushi.14-00235-4 · Cited by 5 · see citing works
No Effect of Adjunctive Minocycline Treatment on Body Metabolism in Patients With Schizophrenia
Liu, F., Xie, L., Zhang, B., Ruan, Y., Zeng, Y., Xu, X., Zhao, J., & Fan, X. (2018) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000841 · Cited by 5 · see citing works
Neuroinflammation in Schizophrenia Focused on the Pharmacological and Therapeutic Evidence
Xu, H. (2015) · Pharmacologia · doi:10.5567/pharmacologia.2015.438.453 · Cited by 4 · see citing works
Gut-Brain Axis: The Role of Gut Microbiota in the Psychiatric Disorders
Evrensel, A., & Ceylan, M. E. (2015) · Psikiyatride Guncel Yaklasimlar - Current Approaches in Psychiatry · doi:10.5455/cap.20150128123852 · Cited by 4 · see citing works
Herbal Medicine in the Treatment of Obsessive Compulsive Disorder: A Review
Zamani, Z., & Akhondzadeh, S. (2019) · Journal of Medicinal Plants · doi:10.29252/jmp.3.71.1 · Cited by 4 · see citing works
Self-citationSo, M. T.-W., Ullah, A., Waris, A., & Alhumaydhi, F. A. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26199814 · Cited by 3 · see citing works
Arabzadeh, S., Zeinoddini, A., Mostafavi, S., Hamedi, M., Ehyaii, A., Ghaleiha, A., Zeinoddini, A., & Akhondzadeh, S. (2018) · Europe PMC (PubMed Central) · Cited by 3 · see citing works
Self-citationBrief psychotic disorder related to areca nut use: a case report
Li, S., Li, Z., Chen, J., Wang, F., Ou, Y., Huang, Y., & Li, Z. (2024) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2024.1360493 · Cited by 2 · see citing works
Günther, A., Chini, M., Bitzenhofer, S. H., Marquardt, A., & Hanganu‐Opatz, I. L. (2026) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2026.106470 · Cited by 2 · see citing works
The Influence of Diet and the Gut Microbiota in Schizophrenia
Ghomi, R. H., & Nemani, K. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-802304-4.00016-5 · Cited by 2 · see citing works
The efficacy of complementary use of memantine in treatment of schizophrenia with chronic course
fakhkhari, A. (2013) · Cited by 2 · see citing works
Modulators of Glutamatergic Signaling as Potential Treatments for Autism Spectrum Disorders
Sogos, C., & Fioriello, F. (2022) · Springer eBooks · doi:10.1007/978-3-030-87480-3_20 · Cited by 2 · see citing works
Add-On Pharmacotherapy in Schizophrenia: Does It Improve Long-Term Outcomes? A Systematic Review
Smyrnis, A., Smyrnis, G., & Smyrnis, N. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14217847 · Cited by 2 · see citing works
Li, H., Shen, H., Duan, X., Guo, M., & Liu, X. (2026) · BMC Psychiatry · doi:10.1186/s12888-026-07774-y · Cited by 1 · see citing works
Minocycline as an Evidence-Based Adjunct Treatment in Schizophrenia
Kelly, D. L., & Wehring, H. J. (2018) · Psychiatric Annals · doi:10.3928/00485713-20180413-01 · Cited by 1 · see citing works
Neuroinflamation Treatment Options in Resistant Schizophrenia—State of the Art
de Sá, Z. C., Buinho, A., de Oliveira, T. M., Soares, F. R., Rema, J., & Novais, F. (2025) · Current Treatment Options in Psychiatry · doi:10.1007/s40501-025-00356-x · Cited by 1 · see citing works
Myint, A.-M., & Schwarz, M. (2015) · Current topics in neurotoxicity · doi:10.1007/978-3-319-13602-8_10
Investigating neurobiological mechanisms linking depression and inflammation
Hasebe, K. (2017) · Figshare
Gut Microbiota in Brain diseases
Salami, M. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-819265-8.00040-1
Gao, P., Huang, M., Ono, N., Kanaya, S., & Altaf-Ul-Amin, M. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.06.16.444960
Anti-inflammatory Agents for Patients with Schizophrenia
van Beveren, N. J. M., Çakici, N., & Sommer, I. E. (2021) · Springer eBooks · doi:10.1007/978-3-030-71229-7_22
- Authors
- Khodaie-Ardakani, M.-R., Mirshafiee, O., Farokhnia, M., Tajdini, M., Hosseini, S.-M.-R., Modabbernia, A., Rezaei, F., Salehi, B., Yekehtaz, H., Ashrafi, M., Tabrizi, M., & Akhondzadeh, S.
- Affiliations
- Razi Hospital (IR)
- Roozbeh Hospital (IR)
- Kurdistan University of Medical Sciences (IR)
- Arak University of Medical Sciences (IR)
- Tehran University of Medical Sciences (IR)
- Corresponding author
- Akhondzadeh, Shahin
- ORCID
- Venue
- Psychiatry Research
- Publisher
- Elsevier BV
- Published
- 2014-03
- Volume
- 215
- Issue
- 3
- Pages
- 540-546
- ISSN
- 0165-1781 (ISSN-L)
- OpenAlex
- W2070688969
- Cited by
- 104
- References
- 33
- Citations by year
- 2026: 5 · 2025: 5 · 2024: 3 · 2023: 4 · 2022: 4 · 2021: 11 · 2020: 6 · 2019: 5 · 2018: 16 · 2017: 9 · 2016: 14 · 2015: 14 · 2014: 6 · 2013: 2
- FWCI
- 10.94
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Psychiatry Research (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Tehran University of Medical Sciences (11921)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Health Sciences › Medicine › Pharmacology › Treatment of Major Depression
- Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
- Keywords
- minocycline, risperidone, schizophrenia, negative symptoms, adjunctive therapy, chronic schizophrenia, PANSS, extrapyramidal symptoms, depression, tolerability, neuroprotection
- MeSH terms
- Adult, Anti-Bacterial Agents, Double-Blind Method, Drug Therapy, Combination, Female, Humans, Male, Middle Aged, Minocycline, Psychiatric Status Rating Scales, Schizophrenia, Schizophrenic Psychology, Antipsychotic Agents, Treatment Outcome, Risperidone
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
